

Olivia M Dean

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3724961/publications.pdf>

Version: 2024-02-01

123
papers

7,737
citations

81743

39
h-index

53109

85
g-index

125
all docs

125
docs citations

125
times ranked

9233
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 67-77.	1.3	11
2	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2022, 27, 716-723.	0.7	3
3	The influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 350-362.	2.0	9
4	The Australian Genetics of Depression Study: New Risk Loci and Dissecting Heterogeneity Between Subtypes. <i>Biological Psychiatry</i> , 2022, 92, 227-235.	0.7	18
5	Effect of Glucocorticoid and 11 β -Hydroxysteroid-Dehydrogenase Type 1 (11 β -HSD1) in Neurological and Psychiatric Disorders. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 387-398.	1.0	4
6	N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110550.	2.5	5
7	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 615-627.	2.2	9
8	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	1.3	49
9	Attachment insecurity partially mediates the relationship between childhood trauma and depression severity in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 591-603.	2.2	9
10	Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder. <i>Frontiers in Pharmacology</i> , 2022, 13, 873271.	1.6	7
11	Common effects of bipolar disorder medications on expression quantitative trait loci genes. <i>Journal of Psychiatric Research</i> , 2022, 150, 105-112.	1.5	2
12	Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression. <i>Acta Neuropsychiatrica</i> , 2022, 34, 220-227.	1.0	7
13	Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 300-310.	0.9	2
14	Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7180.	1.8	8
15	Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7508.	1.8	2
16	Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 784-798.	1.3	16
17	Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial. <i>Drug and Alcohol Review</i> , 2021, 40, 1249-1255.	1.1	8
18	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Systematic review and meta-analysis of the role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders. <i>Journal of Affective Disorders</i> , 2021, 279, 711-721.	2.0	9
20	A novel way to quantify schizophrenia symptoms in clinical trials. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13398.	1.7	13
21	A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 262-273.	0.9	11
22	Relationships Between Different Dimensions of Social Support and Suicidal Ideation in Young People with Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2021, 281, 714-720.	2.0	21
23	The evolution of clinical trials in response to COVID-19. <i>Medical Journal of Australia</i> , 2021, 214, 332.	0.8	4
24	The Added Burden of Personality Disorder on Subsidized Australian Health Service Utilization Among Women With Mental State Disorder. <i>Frontiers in Global Women S Health</i> , 2021, 2, 615057.	1.1	1
25	Influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e044569.	0.8	1
26	Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: A systematic review and meta analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 123, 1-13.	2.9	39
27	Treatment of Refractory Obsessive-Compulsive Disorder with Nutraceuticals (TRON): A 20-week, open label pilot study. <i>CNS Spectrums</i> , 2021, , 1-35.	0.7	4
28	Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7164.	1.8	11
29	N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. <i>EClinicalMedicine</i> , 2021, 38, 101005.	3.2	12
30	Statins: Neurobiological underpinnings and mechanisms in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 693-708.	2.9	15
31	Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. <i>Journal of Clinical Medicine</i> , 2021, 10, 4095.	1.0	8
32	Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial. <i>Journal of Psychiatric Research</i> , 2021, 142, 376-383.	1.5	1
33	Cognitive insight, medication adherence and methamphetamine cessation in people enrolled in a pharmacotherapy trial for methamphetamine use. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108473.	1.5	0
34	Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: PÂ©ricarpe dâ€™TMappoint <i>Garcinia mangostana</i> Linn (mangoustan) pour la schizophrÃ©nie : un essai dâ€™TMefficacitÃ© de 24 semaines, Ã double insu, randomisÃ© et contrÃ© par placebo. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 354-366.	0.9	3
35	A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. <i>European Neuropsychopharmacology</i> , 2021, 53, 120-126.	0.3	0
36	Dietary quality and nutrient intake in adults with obsessive-compulsive disorder. <i>BJPsych Open</i> , 2021, 7, .	0.3	4

#	ARTICLE	IF	CITATIONS
37	Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 14-21.	0.9	7
38	The effect of blueberry interventions on cognitive performance and mood: A systematic review of randomized controlled trials. <i>Brain, Behavior, and Immunity</i> , 2020, 85, 96-105.	2.0	67
39	Improvement of cognitive function in schizophrenia with <i>N</i> -acetylcysteine: A theoretical review. <i>Nutritional Neuroscience</i> , 2020, 23, 139-148.	1.5	29
40	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 775-783.	1.3	27
41	In response to "There is no meta-analytic evidence of blueberries improving cognitive performance or mood". <i>Brain, Behavior, and Immunity</i> , 2020, 85, 193.	2.0	0
42	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101486.	0.9	11
43	Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive <i>N</i> -acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 159-172.	1.3	11
44	Meta-analysis of randomised controlled trials with <i>N</i> -acetylcysteine in the treatment of schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 453-466.	1.3	58
45	Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 306-318.	0.9	9
46	Insight in substance use disorder: A systematic review of the literature. <i>Addictive Behaviors</i> , 2020, 111, 106549.	1.7	25
47	Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis. <i>JAMA Network Open</i> , 2020, 3, e2024335.	2.8	19
48	Personality disorder increases risk of low quality of life among women with mental state disorders. <i>Comprehensive Psychiatry</i> , 2020, 102, 152193.	1.5	7
49	Prebiotics, probiotics, fermented foods and cognitive outcomes: A meta-analysis of randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 472-484.	2.9	50
50	Anti-inflammatory treatment of bipolar depression: promise and disappointment. <i>Lancet Psychiatry</i> , 2020, 7, 467-468.	3.7	9
51	Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e035080.	0.8	1
52	Studies on Haloperidol and Adjunctive \pm -Mangostin or Raw <i>Garcinia mangostana</i> Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats. <i>Frontiers in Psychiatry</i> , 2020, 11, 121.	1.3	9
53	Does <i>N</i> -acetylcysteine improve behaviour in children with autism?: A mixed-methods analysis of the effects of <i>N</i> -acetylcysteine. <i>Journal of Intellectual and Developmental Disability</i> , 2019, 44, 474-480.	1.1	3
54	The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. <i>Lancet Psychiatry</i> , 2019, 6, 735-744.	3.7	63

#	ARTICLE	IF	CITATIONS
55	Measuring cognitive insight in people with problematic substance use: An exploration of the factor validity of the Beck Cognitive Insight Scale. <i>Drug and Alcohol Review</i> , 2019, 38, 622-629.	1.1	6
56	Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis – A possible therapeutic mechanism. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 766-777.	1.3	5
57	N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 555.	0.7	8
58	Modulation of high fat diet-induced microbiome changes, but not behaviour, by minocycline. <i>Brain, Behavior, and Immunity</i> , 2019, 82, 309-318.	2.0	10
59	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	1.0	28
60	A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. <i>BMC Medicine</i> , 2019, 17, 18.	2.3	73
61	A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine (dependence). <i>Trials</i> , 2019, 20, 325.	0.7	14
62	Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 297-307.	0.9	5
63	Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2019, 77, 557-571.	2.6	59
64	Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review. <i>BMJ Open</i> , 2019, 9, e025640.	0.8	5
65	Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e025145.	0.8	5
66	Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis. <i>Trials</i> , 2019, 20, 203.	0.7	2
67	The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 115.	1.3	16
68	Efficacy of adjunctive <i>Garcinia mangostana</i> Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 245-253.	0.9	8
69	Considerations when selecting pharmacotherapy for nicotine dependence. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 245-250.	0.9	0
70	Mechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 582-591.	1.0	19
71	An update on adjunctive treatment options for bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 87-96.	1.1	25
72	Youth Depression Alleviation – Augmentation with an anti-inflammatory agent (Rosuvastatin): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin. <i>Microbial Biotechnology</i> , 2018, 12, 45-54.	0.9	15

#	ARTICLE	IF	CITATIONS
73	Post-Operative Cognitive Dysfunction: An exploration of the inflammatory hypothesis and novel therapies. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 116-133.	2.9	210
74	<i>Garcinia mangostana</i> Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat. <i>Metabolic Brain Disease</i> , 2018, 33, 467-480.	1.4	24
75	Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. <i>Acta Neuropsychiatrica</i> , 2018, 30, 334-341.	1.0	16
76	A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 241-249.	1.3	48
77	A potential role for N-acetylcysteine in the management of methamphetamine dependence. <i>Drug and Alcohol Review</i> , 2017, 36, 153-159.	1.1	25
78	A model of the mitochondrial basis of bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 1-20.	2.9	118
79	A Review of the Theoretical and Biological Understanding of the Nocebo and Placebo Phenomena. <i>Clinical Therapeutics</i> , 2017, 39, 469-476.	1.1	59
80	The effect of N-acetylcysteine (NAC) on human cognition – A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 78, 44-56.	2.9	82
81	Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 829-840.	1.3	75
82	Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. <i>Acta Neuropsychiatrica</i> , 2017, 29, 337-346.	1.0	25
83	The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 165.	0.7	11
84	Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 72, 73-86.	2.5	31
85	A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 65, 185-194.	2.9	256
86	N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. <i>BMC Psychiatry</i> , 2016, 16, 320.	1.1	34
87	Participant Characteristics as Modifiers of Response to N-Acetyl Cysteine (NAC) in Obsessive-Compulsive Disorder. <i>Clinical Psychological Science</i> , 2016, 4, 1104-1111.	2.4	8
88	N-Acetylcysteine in Depressive Symptoms and Functionality. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e457-e466.	1.1	93
89	N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 12-24.	0.9	78
90	Tobacco Use in Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 1-11.	0.9	49

#	ARTICLE	IF	CITATIONS
91	Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 03-12.	0.9	38
92	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. <i>Psychiatry Research</i> , 2015, 230, 982-983.	1.7	11
93	Fostering early and mid-career research in affective disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 387-388.	1.3	1
94	Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 294-321.	2.9	350
95	N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. <i>CNS Drugs</i> , 2015, 29, 801-809.	2.7	59
96	Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 57, 69-75.	2.5	29
97	Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder. <i>Current Neuropharmacology</i> , 2015, 13, 656-662.	1.4	11
98	Oxidative & nitrosative stress in depression: Why so much stress?. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 45, 46-62.	2.9	324
99	Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 347-354.	1.3	23
100	The promise of N-acetylcysteine in neuropsychiatry. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 167-177.	4.0	359
101	Putative neuroprotective agents in neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 42, 135-145.	2.5	88
102	The chemistry and biological activities of N-acetylcysteine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 4117-4129.	1.1	620
103	A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 564-568.	1.3	50
104	Effects of N-acetyl cysteine on cognitive function in bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 514-517.	1.0	45
105	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. <i>BMC Medicine</i> , 2012, 10, 91.	2.3	81
106	Translating the Rosetta Stone of N-Acetylcysteine. <i>Biological Psychiatry</i> , 2012, 71, 935-936.	0.7	20
107	Minocycline. <i>CNS Drugs</i> , 2012, 26, 391-401.	2.7	117
108	N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2011, 499, 149-153.	1.0	75

#	ARTICLE	IF	CITATIONS
109	N-acetylcysteine for major depressive episodes in bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 374-378.	0.9	99
110	Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2011, 23, 87-88.	1.0	7
111	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. <i>Journal of Affective Disorders</i> , 2011, 135, 389-394.	2.0	162
112	N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 78-86.	1.4	373
113	Qualitative Methods in Early-Phase Drug Trials. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 909-913.	1.1	29
114	Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 97, 293-300.	1.3	15
115	Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. <i>European Journal of Pharmacology</i> , 2010, 649, 224-228.	1.7	54
116	Oxidative pathways as a drug target for the treatment of autism. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1301-1310.	1.5	35
117	Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. <i>Behavioural Brain Research</i> , 2009, 198, 258-262.	1.2	63
118	Nail-Biting Stuff? The Effect of N-acetyl Cysteine on Nail-Biting. <i>CNS Spectrums</i> , 2009, 14, 357-360.	0.7	53
119	Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 851-76.	1.0	821
120	N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 361-368.	0.7	489
121	N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder—A Double-Blind Randomized Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 468-475.	0.7	452
122	Glutathione: a novel treatment target in psychiatry. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 346-351.	4.0	166
123	N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1955-1962.	1.4	335